Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction

BioCryst Pharmaceuticals Inc.

www.biocryst.com

Latest From BioCryst Pharmaceuticals Inc.

Bookmark
  • Analysis

Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

By Mandy Jackson

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Financing Business Strategies
Bookmark
  • News

Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers

By Ian Haydock, Jung Won Shin and Joseph Haas

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.

Deals Business Strategies
Bookmark
  • Analysis

Mixed Responses To BioCryst's Oral Phase III HAI Therapy, BCX7353

By John Davis

BioCryst’s BCX7353 could be the first oral therapy to prevent hereditary angioedema attacks, but it might not work in all patients, according to data from the Phase III APeX-2 study.

Immune Disorders Clinical Trials
Bookmark
  • News

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

By Mandy Jackson

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioCryst Pharmaceuticals Inc.
  • Senior Management
  • Jon P Stonehouse, Pres. & CEO
    Thomas R Staab, SVP, CFO
    William P Sheridan, SVP, CMO
    Megan Sniecinski , SVP, CBO
  • Contact Info
  • BioCryst Pharmaceuticals Inc.
    Phone: (919) 859-1302
    4505 Emperor Blvd., Ste. 200
    Durham, NC 27703
    USA
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By